BIOTALYS NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 EUR | 0.00% |
|
+1.64% | -33.62% |
| 05-02 | Biotalys Starts Field Trials for Second Biofungicide | CI |
| 04-30 | Biotalys Announces Board and Committee Changes | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 219.3 | 210.5 | 149.9 | 99.69 | - | - |
| Enterprise Value (EV) 1 | 170.5 | 180.8 | 149.9 | 99.69 | 99.69 | 99.69 |
| P/E ratio | -6.47 x | -9.19 x | - | - | - | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 110 x | 71.4 x | 57.4 x | 33.2 x | 33.2 x | 33.2 x |
| EV / Revenue | 110 x | 71.4 x | 57.4 x | 33.2 x | 33.2 x | 33.2 x |
| EV / EBITDA | -13.2 x | -10 x | - | -11.3 x | -11.1 x | -10.8 x |
| EV / FCF | -12,132,729 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | 5.52 x | - | - | - | - |
| Nbr of stocks (in thousands) | 30,806 | 30,949 | 32,095 | 32,157 | - | - |
| Reference price 2 | 7.120 | 6.800 | 4.670 | 3.100 | 3.100 | 3.100 |
| Announcement Date | 22-03-11 | 23-02-28 | 24-02-22 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.838 | 1.995 | 2.949 | 2.611 | 3 | 3 | 3 |
| EBITDA 1 | - | -16.61 | -20.96 | - | -8.8 | -9 | -9.2 |
| EBIT | - | -18.08 | -22.53 | - | - | - | - |
| Operating Margin | - | -906.22% | -764.02% | - | - | - | - |
| Earnings before Tax (EBT) | - | -16.91 | -22.77 | - | - | - | - |
| Net income | -13.2 | -16.93 | -22.73 | - | - | - | - |
| Net margin | -134.17% | -848.57% | -770.8% | - | - | - | - |
| EPS | - | -1.100 | -0.7400 | - | - | - | - |
| Free Cash Flow | - | -18.08 | - | - | - | - | - |
| FCF margin | - | -906.17% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21-04-19 | 22-03-11 | 23-02-28 | 24-02-22 | - | - | - |
1EUR in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | -10.66 |
| Net margin | - |
| EPS 2 | -0.3400 |
| Dividend per Share | - |
| Announcement Date | 23-08-23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 48.9 | 29.7 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -18.1 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -40% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | 1.230 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 1.32 | - | - | - | - | - |
| Capex / Sales | - | 66.37% | - | - | - | - | - |
| Announcement Date | 21-04-19 | 22-03-11 | 23-02-28 | 24-02-22 | - | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.1
EUR
Average target price
6
EUR
Spread / Average Target
+93.55%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.62% | 107M | |
| -6.20% | 6.8B | |
| +9.27% | 3.21B | |
| +10.62% | 844M | |
| +6.59% | 386M | |
| +12.43% | 295M |
- Stock Market
- Equities
- BTLS Stock
- Financials Biotalys NV
